Assessment of Efficiency and Safety of Apatinib in Advanced Bone and Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis

Continuous endoglin (CD105) overexpression disrupts angiogenesis and facilitates tumor cell metastasis

(2020) Claudia Ollauri-Ibáñez et al.   ANGIOGENESIS

Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma

(2020) Zhichao Tian et al.   INVESTIGATIONAL NEW DRUGS

The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis

(2020) Jia-Yong Liu et al.   International Journal of Clinical Oncology

Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial

(2020) Jieqiong Liu et al.   Journal for ImmunoTherapy of Cancer

Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma

(2020) Yinli Yang et al.   CANCER GENE THERAPY

The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution

(2020) Yitian Wang et al.   Cancer Management and Research

Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study

(2020) Lu Xie et al.   Cancer Management and Research

Desmoid tumours stalled by sorafenib

(2019) Katharine H. Wrighton   Nature Reviews Clinical Oncology

Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer

(2019) Sha Zhao et al.   Cancer Immunology Research

Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy

(2019) Zhichao Tian et al.   MEDICINE

The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study

(2019) Tomoki Nakamura et al.   CLINICAL & EXPERIMENTAL METASTASIS

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma

(2019) Lara E. Davis et al.   JOURNAL OF CLINICAL ONCOLOGY

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial

(2019) Ian Judson et al.   LANCET ONCOLOGY

Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial

(2019) Silvia Stacchiotti et al.   LANCET ONCOLOGY

Efficacy and safety of apatinib in advanced sarcoma

(2019) Yao Weitao et al.   ANTI-CANCER DRUGS

Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846

(2019) Xinyue Liu et al.   BIOMEDICINE & PHARMACOTHERAPY

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial

(2018) Jorge E. Cortes et al.   BLOOD

Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China

(2018) Lu Xie et al.   BMC CANCER

Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report

(2018) Lishu Yang et al.   BMC CANCER

Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study

(2018) Baorang Zhu et al.   CANCER BIOLOGY & THERAPY

Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients With Refractory Metastatic Soft Tissue Sarcoma

(2018) Yihebali Chi et al.   CLINICAL CANCER RESEARCH

Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers

(2018) Lesley J. Scott   DRUGS

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

(2018) Michael B Atkins et al.   LANCET ONCOLOGY

Efficacy and safety of apatinib combined with chemotherapy for the treatment of advanced gastric cancer in the Chinese population: a systematic review and meta-analysis

(2018) HongGang Cheng et al.   Drug Design Development and Therapy

Pro- and antiangiogenic therapies: current status and clinical implications

(2018) Ruslan Rust et al.   FASEB JOURNAL

Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis

(2018) Jinmin Xue et al.   OncoTargets and Therapy

Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–small-cell Lung Carcinoma

(2018) Beth A. Hellerstedt et al.   Clinical Lung Cancer

Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study

(2018) S. Stacchiotti et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

(2018) Florence Duffaud et al.   LANCET ONCOLOGY

Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial

(2018) Javier Martin-Broto et al.   LANCET ONCOLOGY

Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial

(2018) Lu Xie et al.   ONCOLOGIST

Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance

(2017) Fang Li et al.   EUROPEAN JOURNAL OF CANCER

Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma

(2017) Kuisheng Liu et al.   Cell Death & Disease

Advanced alveolar soft part sarcoma responds to apatinib

(2017) Yong Zhou et al.   Oncotarget

Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward

(2016) Joanne P. Lagmay et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial

(2016) Olivier Mir et al.   LANCET ONCOLOGY

Refinements in Sarcoma Classification in the Current 2013 World Health Organization Classification of Tumours of Soft Tissue and Bone

(2016) Vickie Y. Jo et al.   Surgical Oncology Clinics of North America

Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway

(2016) Chen Lin et al.   Oncotarget

Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?

(2015) Amit Mahipal et al.   Journal of the National Comprehensive Cancer Network

Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group

(2015) AeRang Kim et al.   PEDIATRIC BLOOD & CANCER

Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer

(2014) Xichun Hu et al.   BMC CANCER

A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis

(2014) Jae-Cheol Jo et al.   INVESTIGATIONAL NEW DRUGS

Sorafenib in patients with progressive epithelioid hemangioendothelioma

(2013) Christine Chevreau et al.   CANCER

Cediranib for Metastatic Alveolar Soft Part Sarcoma

(2013) Shivaani Kummar et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiangiogenic Therapies: Going beyond Their Limits

(2013) L. Moserle et al.   Cancer Discovery

Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy

(2012) A. Santoro et al.   ANNALS OF ONCOLOGY

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study

(2011) G. Grignani et al.   ANNALS OF ONCOLOGY

Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas

(2011) Margaret von Mehren et al.   CANCER

Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters

(2010) Y.-j. Mi et al.   CANCER RESEARCH

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial

(2009) Simon Pacey et al.   INVESTIGATIONAL NEW DRUGS

Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas

(2009) Suzanne George et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

(2009) Stefan Sleijfer et al.   JOURNAL OF CLINICAL ONCOLOGY